RecruitingRecruiting
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501 · Neurocrine Biosciences
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
About this study
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Eligibility criteria
Key Inclusion Criteria:
* Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.
* Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.
* Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.
* Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1).
* Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.
Key Exclusion Criteria:
* A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.
* Are considered by the investigator to be at imminent risk of suicide or injury to self or others.
* Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.
Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Study design
Enrollment target: 550 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2025-08-18
Estimated completion: 2028-07
Last updated: 2026-07-24
Interventions
Drug: NBI-1065845Drug: Placebo
Primary outcomes
- • Time from Randomization to Relapse (From randomization to the earliest of relapse or end-of study (up to approximately 32 months))
Sponsor
Neurocrine Biosciences · industry
Contacts & investigators
ContactNeurocrine Medical Information Call Center · contact · medinfo@neurocrine.com · 1-877-641-3461
InvestigatorClinical Development Lead · study_director, Neurocrine Biosciences
All locations (60)
Neurocrine Clinical SiteRecruiting
Oceanside, California, United States
Neurocrine Clinical SiteRecruiting
Orange, California, United States
Neurocrine Clinical SiteRecruiting
San Jose, California, United States
Neurocrine Clinical SiteRecruiting
New Haven, Connecticut, United States
Neurocrine Clinical SiteRecruiting
Miami Gardens, Florida, United States
Neurocrine Clinical SiteRecruiting
Orlando, Florida, United States
Neurocrine Clinical SiteRecruiting
Palm Bay, Florida, United States
Neurocrine Clinical SiteRecruiting
Tampa, Florida, United States
Neurocrine Clinical SiteRecruiting
Iowa City, Iowa, United States
Neurocrine Clinical SiteRecruiting
Marrero, Louisiana, United States
Neurocrine Clinical SiteRecruiting
O'Fallon, Missouri, United States
Neurocrine Clinical SiteRecruiting
Albuquerque, New Mexico, United States
Neurocrine Clinical SiteRecruiting
Glen Oaks, New York, United States
Neurocrine Clinical SiteRecruiting
Charlotte, North Carolina, United States
Neurocrine Clinical SiteRecruiting
Edmond, Oklahoma, United States
Neurocrine Clinical SiteRecruiting
Oklahoma City, Oklahoma, United States
Neurocrine Clinical SiteRecruiting
Philadelphia, Pennsylvania, United States
Neurocrine Clinical SiteActive Not Recruiting
Austin, Texas, United States
Neurocrine Clinical SiteRecruiting
Bellaire, Texas, United States
Neurocrine Clinical SiteTerminated
Friendswood, Texas, United States
Neurocrine Clinical SiteRecruiting
Stafford, Texas, United States
Neurocrine Clinical SiteRecruiting
Wichita Falls, Texas, United States
Neurocrine Clinical SiteRecruiting
Draper, Utah, United States
Neurocrine Clinical SiteRecruiting
Roanoke, Virginia, United States
Neurocrine Clinical SiteRecruiting
Carlton, Victoria, Australia
Neurocrine Clinical SiteRecruiting
Melbourne, Victoria, Australia
Neurocrine Clinical SiteRecruiting
Parkville, Victoria, Australia
Neurocrine Clinical SiteRecruiting
Sofia, Bulgaria
Neurocrine Clinical SiteRecruiting
Sofia, Bulgaria
Neurocrine Clinical SiteRecruiting
Sofia, Bulgaria
Neurocrine Clinical SiteRecruiting
Sofia, Bulgaria
Neurocrine Clinical SiteRecruiting
Calgary, Alberta, Canada
Neurocrine Clinical SiteRecruiting
North Vancouver, British Columbia, Canada
Neurocrine Clinical SiteRecruiting
Kingston, Ontario, Canada
Neurocrine Clinical SiteRecruiting
Sherbrooke, Quebec, Canada
Neurocrine Clinical SiteRecruiting
Toronto, Canada
Neurocrine Clinical SiteRecruiting
Tallinn, Estonia
Neurocrine Clinical SiteRecruiting
Tallinn, Estonia
Neurocrine Clinical SiteRecruiting
Tartu, Estonia
Neurocrine Clinical SiteWithdrawn
Milan, Italy
Neurocrine Clinical SiteRecruiting
Roma, Italy
Neurocrine Clinical SiteRecruiting
Rome, Italy
Neurocrine Clinical SiteRecruiting
Torino, Italy
Neurocrine Clinical SiteRecruiting
Bialystok, Poland
Neurocrine Clinical SiteRecruiting
Bydgoszcz, Poland
Neurocrine Clinical SiteRecruiting
Gdansk, Poland
Neurocrine Clinical SiteRecruiting
Belgrade, Serbia
Neurocrine Clinical SiteRecruiting
Kovin, Serbia
Neurocrine Clinical SiteRecruiting
Kragujevac, Serbia
Neurocrine Clinical SiteRecruiting
Ansan-si, Gyeonggi-do, South Korea
Neurocrine Clinical SiteRecruiting
Seoul, South Korea
Neurocrine Clinical SiteRecruiting
Seoul, South Korea
Neurocrine Clinical SiteRecruiting
Seoul, South Korea
Neurocrine Clinical SiteRecruiting
Alcorcón, Madrid, Spain
Neurocrine Clinical SiteRecruiting
Barcelona, Spain
Neurocrine Clinical SiteRecruiting
Barcelona, Spain
Neurocrine Clinical SiteRecruiting
Keelung, Taiwan
Neurocrine Clinical SiteRecruiting
Taipei, Taiwan
Neurocrine Clinical SiteRecruiting
Taipei, Taiwan
Neurocrine Clinical SiteRecruiting
Taipei, Taiwan